Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial - Concepedia

Concepedia

Publication | Open Access

Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial

DOI Full Paper Access

23

Citations

2

References

2025

Year

Thomas Powles, Michiel S. van der Heijden, Y. Loriot, Jens Bedke, Begoña P. Valderrama, Ganesh R. Iyer, Eiji Kikuchi, Jean Hoffman‐Censits, Christof Vulsteke, A. Drakaki,

Annals of Oncology

References

	Year	Citations

Page 1